Pyxis Oncology, Inc.
PYXS
Rank in Stocks
#19387
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company... Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Share Price
$1.70
Last synced: 2026-11-09
Market Cap
$107.70M
Change (1 day)
2.41%
Change (1 year)
-62.80%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pyxis Oncology, Inc. (PYXS)
Category
Healthcare
Operating Margin for Pyxis Oncology, Inc. (PYXS)
Operating Margin as of November 2026 TTM: -834.44%
According to Pyxis Oncology, Inc.'s latest financial reports, its current operating margin (TTM) is -834.44%. At the end of 2025 the company had an operating margin of -609.18%.
Operating Margin history for Pyxis Oncology, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -834.44% | 36.98% |
| 2025 | -609.18% | 9.95% |
| 2024 | -554.07% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.05% |
US
|
|
| -149.01% | -99.82% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.04% |
BE
|
|
| 29.35% | -100.04% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Pyxis Oncology, Inc.'s operating margin
What is Pyxis Oncology, Inc.'s operating margin?
Pyxis Oncology, Inc.'s operating margin is -834.44%, as of Nov 2026.
What was Pyxis Oncology, Inc.'s operating margin in 2025?
In 2025, Pyxis Oncology, Inc.'s operating margin was -609.18%, compared with -554.07% in 2024.
How has Pyxis Oncology, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Pyxis Oncology, Inc.'s operating margin was highest in 2023 (0.00%) and lowest in 2025 (-609.18%).
How does Pyxis Oncology, Inc.'s operating margin compare with similar companies?
Pyxis Oncology, Inc.'s operating margin (-834.44%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.